All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How should novel agents be used in the current treatment pathways for GvHD?

Jul 20, 2022
Learning objective: After listening to this discussion, learners will be able to cite novel agents being used in the treatment of GvHD.

During the GvHD Hub Steering Committee meeting on April 5, 2022, key opinion leaders met to debate the question of how novel agents should be used in the current treatment pathways for GvHD. This recorded discussion was chaired by Amin Alousi, and featured Hildegard Greinix, Mohamad Mohty, Florent Malard, and Arnon Nagler.

How should novel agents be used in the current treatment pathways for GvHD?

Alousi begins the discussion by asking which approaches are commonly used by the steering committee members to sequence therapies for GvHD. Greinix mentions the challenge of working in Europe due ROCK inhibitors not yet being approved. The steering committee talk about the use of ruxolitinib and ibrutinib, as well as steroid tapering schedules. They also discuss when to describe GvHD as refractory and consider the impact of cumulative exposure to steroids.